Glypan-M Tablet is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class drug, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents helps to achieve better glycemic regulation in patients inadequately controlled by diet, exercise, and monotherapy. Glypan-M is typically prescribed as part of a comprehensive diabetes management plan, including diet and lifestyle modifications. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and hypoglycemia, particularly due to the sulfonylurea component. Regular monitoring of blood glucose levels, renal function, and periodic assessment for lactic acidosis symptoms is recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Glypan-M Tablet should be used under strict medical supervision to optimize efficacy and minimize potential risks.